Myomo (NYSEAMERICAN:MYO) Shares Climb 2.5% – Time to Buy?

Shares of Myomo, Inc. (NYSEAMERICAN:MYO) were up 2.5% on Monday. The stock traded as high as $1.7250 and last traded at $1.67. 272,872 shares traded hands during mid-day trading, a decline of 19% from the average daily volume of 337,853 shares. The stock had previously closed at $1.63.

Myomo Stock Down 4.3%

The firm has a market cap of $61.04 million, a P/E ratio of -4.56 and a beta of 1.58. The company has a current ratio of 2.31, a quick ratio of 2.01 and a debt-to-equity ratio of 1.98. The business has a 50-day moving average price of $1.45 and a 200-day moving average price of $1.14.

Myomo (NYSEAMERICAN:MYO) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. Myomo had a negative return on equity of 138.85% and a negative net margin of 33.53%.The firm had revenue of $11.70 million during the quarter, compared to the consensus estimate of $10.35 million. On average, equities analysts forecast that Myomo, Inc. will post -0.32 EPS for the current fiscal year.

Insider Activity at Myomo

In other news, insider Harry Kovelman sold 17,250 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $1.73, for a total value of $29,842.50. Following the completion of the sale, the insider owned 105,983 shares in the company, valued at approximately $183,350.59. The trade was a 14.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 47,738 shares of company stock valued at $70,662. Insiders own 12.14% of the company’s stock.

Myomo Company Profile

Myomo, Inc is a medical robotics company that develops, manufactures and markets wearable powered orthoses designed to help people with impaired arm and hand function regain mobility and perform activities of daily living. Its technology combines sensors, motors and control systems in lightweight, wearable devices that detect a user’s residual muscle signals and provide assistance with movement.

The company’s primary product family is MyoPro, a custom-fitted upper-limb orthosis intended for individuals affected by conditions such as stroke, brachial plexus injury, spinal cord injury, multiple sclerosis and other neuromuscular disorders.